Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Ticagrelor. Fluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Methscopolamine is combined with Buprenorphine. Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Telaprevir. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cicletanine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenelzine. The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Sarilumab. The risk or severity of adverse effects can be increased when Oxitropium is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Ularitide. The serum concentration of Metoprolol can be increased when it is combined with Buprenorphine. Hydroxyamphetamine may increase the analgesic activities of Buprenorphine. Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Dezocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Mephentermine may increase the analgesic activities of Buprenorphine. Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Methazolamide. The risk or severity of adverse effects can be increased when Mecamylamine is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Tolbutamide. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Pheniprazine. Deramciclane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Nelfinavir. The serum concentration of Buprenorphine can be increased when it is combined with Fosaprepitant. The serum concentration of Buprenorphine can be increased when it is combined with Cobicistat. Promethazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Paroxetine. Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Tolvaptan can be increased when it is combined with Buprenorphine. Ethyl chloride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Sulfadiazine. Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorthalidone. Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Quazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Triamterene. The metabolism of Buprenorphine can be decreased when combined with Tamoxifen. Ritanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Promazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Polythiazide. The risk or severity of adverse effects can be increased when Pirenzepine is combined with Buprenorphine. Norflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Buprenorphine. Barbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Canrenoic acid. Ketamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Buprenorphine. The serum concentration of Buprenorphine can be increased when it is combined with Ceritinib. Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Buprenorphine can be decreased when it is combined with Tocilizumab. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Pivhydrazine. Raclopride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Canertinib may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Buprenorphine can be increased when it is combined with Ombitasvir. Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Sulfisoxazole. Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Tipranavir. 7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Phentermine may increase the analgesic activities of Buprenorphine. Codeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Fluorouracil. Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Irbesartan. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Pamabrom. Buprenorphine may increase the serotonergic activities of Levomilnacipran. Reserpine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Benmoxin. The metabolism of Buprenorphine can be decreased when combined with Floxuridine. The metabolism of Buprenorphine can be decreased when combined with Teriflunomide. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Drospirenone. Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Buprenorphine can be increased when it is combined with Palbociclib. Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Homatropine is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid. Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Buprenorphine resulting in a loss in efficacy. Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Tetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Buprenorphine can be decreased when it is combined with Deferasirox. The metabolism of Buprenorphine can be decreased when combined with Posaconazole. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide. The metabolism of Buprenorphine can be decreased when combined with Felodipine. The serum concentration of Rosuvastatin can be increased when it is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Terbinafine. Buprenorphine may decrease the analgesic activities of Bezitramide. Methamphetamine may increase the analgesic activities of Buprenorphine. Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Eltanolone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Ammonium chloride may increase the excretion rate of Buprenorphine which could result in a lower serum level and potentially a reduction in efficacy. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Bendroflumethiazide. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Octamoxin. Buprenorphine may increase the sedative activities of Metyrosine. The metabolism of Buprenorphine can be decreased when combined with Clarithromycin. The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Buprenorphine. Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Tolterodine is combined with Buprenorphine. Clidinium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Vecuronium is combined with Buprenorphine. Thiethylperazine may increase the hypotensive activities of Buprenorphine. Heroin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Ecgonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Amphetamine. Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclopenthiazide. Diazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone. Valproic Acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Methadone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Proparacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Dihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.